Unibest

Pharmaceutical intermediates

Xanomeline Intermediates

1 pharmaceutical intermediate for Xanomeline. Indication: Mental Disorders; Schizophrenia; Alzheimer's Disease.

提交项目All intermediates

About Xanomeline

Originator
Bristol Myers Squibb
Indication
Mental Disorders; Schizophrenia; Alzheimer's Disease
Approved Date
09/26/2024
NCE Patent
09/26/2029
DS/DP
07/21/2030

Available intermediates

1 intermediate currently listed for Xanomeline. Request specifications, documentation or a quotation for any item below.

Xanomeline intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole131986-28-2//

Building toward Xanomeline?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →